Inside PIC/S: Implementing Quality Risk Management - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside PIC/S: Implementing Quality Risk Management
Representatives to the PIC/S provide an example of methodology for implementing ICH Q9.


Pharmaceutical Technology
Volume 33, Issue 12

Implementing the methodology

The PIC/S example of methodology provides pharmaceutical manufacturers with the means, including training tools and a starter kit, to implement quality risk management. The methodology relies on an interactive database that is accessible to industry.


Figure 1: Diagram of a sample operation in service. CAPA is corrective and preventive action. QRM is quality risk management. GMP is good manufacturing practice. (FIGURE 1 IS COURTESY OF THE AUTHORS)
This service, expected to be available soon, will be hosted and maintained on an independent platform that brings together industry, professional associations, and other pharmaceutical manufacturing partners. Drug manufacturers will be able to voluntarily integrate the system on a customer-supplier basis (see Figure 1).

The platform will make available the assistance necessary to implement the method, guarantee confidentiality, and use the information supplied exclusively for implementing the risk-management methodology.

Future prospects

The informal PIC/S working group has performed beta-tests on the proposed methodology. The methodology will, however, need to be placed under change-control management to achieve continuous improvement.

PIC/S will finalize and implement the example of methodology, possibly by the end of 2010.

Read more about the Pharmaceutical Inspection Cooperation Scheme at http://PharmTech.com/pics/ and http://www.picscheme.org/.

Lionel Viornery is an inspector and head of the starting materials inspection unit at the French Health Products Safety Agency (Afssaps), 143/147, bd Anatole, Saint Denis cedex, 93285, France,
. Philippe Legoff is managing director of H&LG Consultants, Biolleyre 5, CH-1066 Epalinges, Switzerland,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here